Commentary: Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis

Commentary: Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis

Bibliographic Details
Main Authors:	Nigel Mackman, Ana T.A. Sachetto
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Series:	Frontiers in Immunology
Subjects:	multiple sclerosis tissue factor inflammation biomarker coagulation
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1320179/full

Similar Items

Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis
by: Tatiana Koudriavtseva, et al.
Published: (2023-07-01)

Could Serum Endocan Be a Vascular Endothelial Marker in Relapsing-Remitting Multiple Sclerosis?
by: Arife Çimen Atalar, et al.
Published: (2021-09-01)

Are Sirtuins 1 and 2 Relevant Players in Relapsing–Remitting Multiple Sclerosis?
by: Justyna Chojdak-Łukasiewicz, et al.
Published: (2024-09-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-11-01)

Coagulation Pathways in Neurological Diseases: Multiple Sclerosis
by: Nicole Ziliotto, et al.
Published: (2019-04-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-12-01)

Multiple Sclerosis Relapsing Remitting Progressive Type
by: Nora Fitri, et al.
Published: (2020-12-01)

Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis
by: Vlad Eugen Tiu, et al.
Published: (2023-02-01)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
by: Arkadiusz Bydliński, et al.
Published: (2024-05-01)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01)

Multimodal evoked potential in monitoring activity relapsing and remitting multiple sclerosis
by: Poverennova I.E., et al.
Published: (2018-03-01)

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments
by: Gutemberg Augusto Cruz dos Santos, et al.
Published: (2022-12-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Cognitive profile of patients with relapsing remitting multiple sclerosis
by: VIVIAN M. ANDRADE, et al.
Published: (1999-09-01)

Analysis of Plasma Using Flow Cytometry Reveals Increased Immune Cell-Derived Extracellular Vesicles in Untreated Relapsing-Remitting Multiple Sclerosis
by: Stephanie N. Blandford, et al.
Published: (2022-03-01)

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis
by: David Haschka, et al.
Published: (2020-04-01)

Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients
by: Samaneh Sabouri, et al.
Published: (2023-07-01)

Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis
by: Izadora Nogueira Fonte Boa, et al.

Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
by: Peter Olujimi Odutola, et al.
Published: (2023-09-01)

Skeletonized mean diffusivity and neuropsychological performance in relapsing‐remitting multiple sclerosis
by: Magdalena Chylińska, et al.
Published: (2022-06-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
by: Dian HE, et al.
Published: (2014-09-01)

Commentary: Acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome) in a patient with relapse-remitting multiple sclerosis.
by: Tatiana eKoudriavtseva
Published: (2016-05-01)

Comparative Profiling of TG2 and Its Effectors in Human Relapsing Remitting and Progressive Multiple Sclerosis
by: Damien D. Pearse, et al.
Published: (2022-05-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis
by: Kabir Magajir Hamid, et al.
Published: (2016-01-01)

Sjögren Syndrome Which Simulates Relapsing Remitting Multiple Sclerosis Clinical Features: Case Report
by: Haluk Gümüş, et al.
Published: (2013-12-01)

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
by: Quentin Howlett-Prieto, et al.
Published: (2023-01-01)

Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing–remitting multiple sclerosis patients
by: Ivan Arisi, et al.
Published: (2023-12-01)

Diagnostic Dilemma: An Atypical Case of Astrocytoma in a Patient with Relapsing–Remitting Multiple Sclerosis
by: Chantal Kahovec, et al.
Published: (2021-06-01)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
by: Mehdi Rezaee, et al.
Published: (2022-01-01)

Comparing Executive Functions in Bilinguals and Monolinguals Suffering From Relapsing-Remitting Multiple Sclerosi
by: Majid Soltani, et al.
Published: (2019-01-01)

Work status and cognitive performance in patients with relapsing remitting multiple sclerosis
by: Evangelina Valeria Cores, et al.
Published: (2019-06-01)

Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis
by: Sherein G. Elgendy, et al.
Published: (2021-10-01)

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
by: Forooz Peiravian, et al.
Published: (2016-09-01)

A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis
by: Domenico Plantone, et al.
Published: (2019-01-01)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
by: Gajofatto A, et al.
Published: (2015-12-01)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023-08-01)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023-01-01)